Spruce Biosciences, Inc. Increase (Decrease) in Deferred Revenue
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Deferred Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-03-09
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $0.00.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was $0.00.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was $0.00.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2025 was $0.00.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$4.91M, a 200.00% decline from fiscal 2023.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2023 was $4.91M.
- Spruce Biosciences, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | -$697.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | -$697.00K derived: sum of 3 quarters · filed 2026-03-09 | -$1.30M derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | -$697.00K derived: sum of 2 quarters · filed 2026-03-09 | -$1.30M derived: sum of 3 quarters · filed 2026-03-09 | -$2.91M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | -$697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.30M derived: sum of 2 quarters · filed 2026-03-09 | -$2.91M derived: sum of 3 quarters · filed 2026-03-09 | -$4.91M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$601.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.21M derived: sum of 2 quarters · filed 2025-11-10 | -$4.21M 10-Q · filed 2025-11-10 | -$7.10M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.61M 10-Q · filed 2025-08-14 | -$6.50M derived: sum of 3 quarters · filed 2025-08-14 | -$9.57M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$2.00M 10-Q · filed 2025-05-06 | -$4.89M derived: sum of 2 quarters · filed 2025-05-06 | -$7.96M derived: sum of 3 quarters · filed 2025-05-06 | -$10.13M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$5.96M derived: sum of 2 quarters · filed 2025-04-15 | -$8.13M derived: sum of 3 quarters · filed 2025-04-15 | $4.91M 10-K · filed 2025-04-15 |
| 2023-09-30 | -$3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$5.24M derived: sum of 2 quarters · filed 2024-11-12 | $7.80M 10-Q · filed 2024-11-12 | $7.80M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $10.87M 10-Q · filed 2024-08-12 | $10.87M derived: sum of 3 quarters · filed 2024-08-12 | $10.87M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $13.04M 10-Q · filed 2024-05-13 | $13.04M derived: sum of 2 quarters · filed 2024-05-13 | $13.04M derived: sum of 3 quarters · filed 2024-05-13 | $13.04M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $0.00 derived: sum of 2 quarters · filed 2024-03-18 | $0.00 derived: sum of 3 quarters · filed 2024-03-18 | $0.00 10-K · filed 2024-03-18 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |